Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Melanoma

1079 - Phase Ⅰc Trial of Intralesional OrienX010 Oncolytic Viral Therapy Into Liver Metastases Among Melanoma Patients (379O)

Date

17 Nov 2017

Session

Melanoma

Presenters

Chuanliang Cui

Citation

Annals of Oncology (2017) 28 (suppl_10): x113-x116. 10.1093/annonc/mdx667

Authors

C. Cui, B. Lian, Z. Chi, L. Si, X. Sheng, T. Bixia, L. Mao, X. Wang, X. Yan, S. Li, L. Zhou, X. Bai, J. Guo

Author affiliations

  • Department Of Renal Cell Carcinoma & Melanoma, Peking University Cancer Hospital-Beijing Cancer Hospital, 100142 - Beijing/CN
More

Resources

Abstract 1079

Background

Liver is a common metastatic site with poor prognosis for melanoma patients, yet limited efficacy has been shown in systemic therapy. OrienX010, a herpes simplex virus type 1-derived oncolytic immunotherapy with expression of gene encoding human GM-CSF, which has shown its efficacy in intralymphatic diseases, was tested for its safety and efficacy in phase Ic trial of intralesional injection into liver metastases.

Methods

OrienX010 (8 × 107 pfu/ml, 10ml per injection) was given intralesionally by ultrasound guide q2w, dose was distributed into 1-2 liver lesions according to tumor size. Tumor assessment was done q8w by CT scan. The primary endpoint was toxicity, secondary endpoints included ORR, DCR and PFS time. Treatment continued until intolerance, or disease progression per iRECIST.

Results

From May 2016, 19 pts have been enrolled, 57.9% male with median age 47 years (32, 61). Mean size of injectable lesions was 30.4mm (10.0-59.0). One had c-Kit mutation (exon 9), no BRAF mutation. All pts had received at least one prior therapy, most (68.4%) were transcatheter hepatic arterial chemoembolization. 79.0% had multiple liver metastases, 57.9% had extrahepatic metastases including lung, bone, abdominal, and distant lymph node. 57.9% had an elevation of serum LDH. Mean injection times were 6 (4-18). AEs were all grade 1/2, pyrexia 84.2%, fatigue 31.6%, injection site pain 26.3%, nausea/vomiting 21.0%, hepatotoxicity 21.0%, leucopenia 10.5%. 12 patients were evaluable till Jan 2017 with median follow-up time of 6.0 months. ORR was 8.3% (1 PR), DCR 41.7% (1 PR, 4 SD) with a time to response 8-16 wks, median PFS was 13.3 wks (95%CI 8.3-18.4), OS not reached.

Conclusions

This is the first trial for evaluating intralesional oncolytic virus injection into liver metastases among melanoma pts- It is tolerable with a potentially beneficial effect. Phase 2 and combination trials are pending.

Clinical trial identification

NCT03048253.

Legal entity responsible for the study

Peking University Cancer Hospital & Institute

Funding

OrienGene Biotechnology Ltd

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings